Pulmonary coin lesion

Summary

Pulmonary coin lesion (MONDO:0006931) is a disease with 2 GWAS associations across 4 studies and 2 clinical trials. A subtype of lung disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• GWAS associations: 2
• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pulmonary coin lesion
Mondo ID	MONDO:0006931
MeSH	D003074
DOID	DOID:5364
UMLS	C0009250
MedGen	3522
Is cancer (heuristic)	no

Also known as: coin lesion of lung (context-dependent category) · coin lesion of lung (finding)

Data availability: 2 GWAS associations (4 studies).

Disease family

This is a subtype of lung disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › lower respiratory tract disorder › lung disorder › pulmonary coin lesion

Related subtypes (32): aspiration pneumonia, lung abscess, pneumonic plague, pulmonary alveolar proteinosis, pulmonary systemic sclerosis, obstructive lung disease, bronchiolitis, pulmonary immaturity, rheumatoid arthritis-associated interstitial lung disease, pulmonary embolism and infarction, acute chest syndrome, fungal lung infectious disease, middle lobe syndrome, pulmonary plasma cell granuloma, silo filler disease, pulmonary alveolar microlithiasis, pulmonary venoocclusive disease, acute lung injury, interstitial lung disease, hantavirus pulmonary syndrome, pulmonary non-tuberculous mycobacterial infection, respiratory failure, lung neoplasm, occupational lung disease, Wilson-Mikity syndrome, neonatal aspiration syndrome, pneumonitis, vanishing lung syndrome, restrictive pulmonary disease, shrinking lung syndrome, dystrophic pulmonary ossification, pulmonary artery disease

Genetics & variants

GWAS landscape

2 GWAS associations across 4 studies. Top hits map to 1 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs55853698	7e-22	CHRNA5	T	0.09
rs55781567	3e-21	CHRNA5	C	0.09

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90476044	Verma A	2024	24,817	406,872	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90478209	Verma A	2024	4,889	112,818	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480274	Verma A	2024	4,889	112,818	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90478208	Verma A	2024	1,850	56,271	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	2
Tier 3: regulatory	0
Tier 4: intronic/intergenic	0

MAF distribution

Bucket	Variants
common (>=0.05)	2
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
5_prime_UTR_variant	2

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs55853698	15	78565597	T>G	0.334	5_prime_UTR_variant	CHRNA5	7e-22	Tier 2: splice/UTR
rs55781567	15	78565644	C>G	0.313	5_prime_UTR_variant	CHRNA5	3e-21	Tier 2: splice/UTR

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01389154	PHASE4	WITHDRAWN	Pilot Study to Measure Lung Biopsy Diagnostic Yield Using Always On Electromagnetic Tip Tracked Devices
NCT01730365	Not specified	COMPLETED	Optical Detection of Malignancy During Percutaneous Interventions